Global Astigmatism Treatment Market Overview:
An astigmatism is a form of vision problem caused by a misalignment of the cornea's shape. The lens of the eye or the cornea on the front side of the eye has an irregular curve in this disease. This induces changes in the way light passes through the retina or refraction. Astigmatism's prevalence varies with age, but it's particularly common in the first few months of life, which fuels the market's growth.
- Rising Prevalence of Eye Disease
- Increasing Innovation in the Field of Eye Care Treatment
- High Adoption of Laser Treatments for Astigmatism Treatment
- Strict Regulations regarding the Treatment
- Growing Global Eye Health Policies in Developing Countries
- Increase in New Innovative Varieties of Eyeglass Lenses
- Lack of Awareness among the User
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Novartis AG (Switzerland), SeaVision USA (United States), Johnson & Johnson Services, Inc. (United States), Bausch & Lomb Incorporated (United States), CooperVision (United States) and Orion Vision Group (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Astigmatism Treatment market by 2026. Considering Market by End User, the sub-segment i.e. Eye Hospitals will boost the Astigmatism Treatment market. Considering Market by Astigmatism, the sub-segment i.e. Myopic Astigmatism will boost the Astigmatism Treatment market.
Latest Market Insights:
In June 2020, Johnson & Johnson Vision announced the Food and Drug Administration (FDA) 510(k) clearance of a new software for the CATALYS Precision Laser System. The new CATALYS cOS 6.0 software with advanced astigmatism management is a collaboration with Cassini Technologies B.V. The new software simplifies astigmatism management workﬂow and increases operational efficiency.
In Feb 2021, To perform patient-specific eye surgery planning, dramatically improve vision and treat astigmatism, Optimo Medical AG and Ansys are incorporating high-fidelity structural simulations with cutting-edge digital twin technology into next-generation surgery preparation. Delivering a solution that powers surgical precision to maximize patient outcomes, the collaboration also drives in silico clinical trials of new eye products — significantly reducing development time and cost.
What Can be Explored with the Astigmatism Treatment Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Astigmatism Treatment Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Astigmatism Treatment
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Astigmatism Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Astigmatism Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Astigmatism Treatment Provider, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.